Article
Biochemistry & Molecular Biology
Oliver Neuhaus, Wolfgang Koehler, Florian Then Bergh, Wolfgang Kristoferitsch, Juergen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl
Summary: This study aimed to investigate the correlation between clinical, neuropsychological, and immunological parameters in RRMS patients with fatigue before and during treatment with GA. After 12 months of treatment, 13 patients showed improvement in all three fatigue assessment scales, while 5 patients deteriorated and 7 patients showed inconsistent effects. Fatigue and overall quality of life improved, but no clear correlation between clinical and molecular effects of GA was found in RRMS patients with fatigue.
Article
Medicine, Research & Experimental
Paulina Maria Reyes-Mata, Argelia Esperanza Rojas-Mayorquin, Lucrecia Carrera-Quintanar, Celia Gonzalez-Castillo, Mario Alberto Mireles-Ramirez, Jose de Jesus Guerrero-Garcia, Daniel Ortuno-Sahagun
Summary: This study aimed to investigate the serum levels of Pleiotrophin (PTN) in patients with Multiple Sclerosis (MS). The results showed that PTN serum levels were significantly higher in RRMS patients compared to the healthy control group, and were associated with sex, body mass index (BMI), and IFN-beta treatment.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Clinical Neurology
Sigal Kaplan, Mikhail Zeygarnik, Tal Stern, Kerstin Hellwig
Summary: This study assessed the impact of in utero exposure to glatiramer acetate (GA) on pregnancy and fetal outcomes. The results showed that exposure to 20 and 40 mg/mL GA in all three trimesters of pregnancy does not appear to be related to adverse pregnancy or infant outcomes.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Mahmoud A. AbdelRazek, Subhash Tummala, Fariha Khalid, Shahamat Tauhid, Youmna Jalkh, Samar Khalil, Shelley Hurwitz, Jonathan Zurawski, Rohit Bakshi
Summary: This study compared gray matter atrophy in patients with multiple sclerosis (MS) treated with glatiramer acetate (GA) and patients with clinically benign MS (BMS). The results showed that there was no significant change in gray matter and whole brain atrophy in the GA group over 2 years, similar to the BMS group.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Ignacio Casanova, Maria I. Dominguez-Mozo, Laura De Torres, Yolanda Aladro-Benito, Angel Garcia-Martinez, Patricia Gomez, Sara Abellan, Esther De Antonio, Roberto Alvarez-Lafuente
Summary: This study investigates the association between a preselected list of miRNAs in the serum of relapsing-remitting multiple sclerosis (RRMS) patients with therapeutic response to Glatiramer Acetate (GA) and clinical evolution. The findings suggest that certain miRNAs may serve as potential biomarkers for disease progression and response to treatment in multiple sclerosis.
Review
Clinical Neurology
Massimiliano Mirabella, Pietro Annovazzi, Wallace Brownlee, Jeffrey A. Cohen, Christoph Kleinschnitz, Christian Wolf
Summary: Earlier diagnosis, access to disease-modifying therapies, and improved supportive care have positively influenced the disease course of multiple sclerosis, leading to improved long-term outcomes for patients. However, the complexity of treatment selection has increased due to the presence of comorbidities, immune senescence, and the growing number of approved therapies.
FRONTIERS IN NEUROLOGY
(2022)
Article
Chemistry, Multidisciplinary
Dina Erzina, Alice Capecchi, Sacha Javor, Jean-Louis Reymond
Summary: Researchers synthesized a library of peptide dendrimers with an amino acid composition similar to GA, some of which were as active as GA. Detailed profiling showed that the best hit dendrimer can induce the differentiation of monocytes towards an M2 state with a distinct immune marker profile. This peptide dendrimer might serve as a starting point to develop a well-defined immunomodulatory analog of GA.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2021)
Article
Immunology
Candace Marsters, Nabeela Nathoo, Lindsay Amatto, Russell Wong, Muhammad N. Mahmood, Jennifer A. McCombe
Summary: Glatiramer acetate, an old and safe therapy for relapsing-remitting multiple sclerosis, can rarely cause urticarial vasculitis. We present a case of normocomplementemic urticarial vasculitis diagnosed by skin punch biopsy in a patient treated with glatiramer acetate for five years. The urticaria resolved after treatment with steroids and an antihistamine, as well as discontinuing glatiramer acetate.
JOURNAL OF NEUROIMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Niloufar Rahiman, Parvin Zamani, Leila Arabi, Seyedeh Hoda Alavizadeh, Aminreza Nikpoor, Mohammad Mashreghi, Ali Badiee, Mahmoud Reza Jaafari
Summary: The study explores the use of liposomal formulations of Glatiramer acetate (GA) to overcome the frequent administration rate required for MS therapy. The results show that liposomal GA has higher efficacy in a murine model of MS, suggesting its potential as a reliable nanomedicine-based platform for MS treatment.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Review
Health Care Sciences & Services
Maria Jose Zarzuelo-Romero, Cristina Perez-Ramirez, Yasmin Cura, Maria Isabel Carrasco-Campos, Luciana Maria Marangoni-Iglecias, Maria Carmen Ramirez-Tortosa, Alberto Jimenez-Morales
Summary: The response to glatiramer acetate (GA) therapy in MS patients may be influenced by genetic polymorphisms in genes such as CD86, CTSS, and FAS. Identifying these polymorphisms could serve as a predictive marker for the response to GA treatment in the future, but further validation studies are needed.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Clinical Neurology
Mathilde Lefort, Sandra Vukusic, Romain Casey, Gilles Edan, Emmanuelle Leray
Summary: Early treatment initiation has a significant impact on disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), reducing the risk of disability development, particularly in older patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Masoumeh Cheshmavar, Omid Mirmosayyeb, Negin Badihian, Shervin Badihian, Vahid Shaygannejad
Summary: The study found that both rituximab (RTX) and glatiramer acetate (GA) did not significantly affect the Expanded Disability Status Scale (EDSS) in secondary progressive multiple sclerosis (SPMS) patients, but were equally effective in reducing relapses.
ACTA NEUROLOGICA SCANDINAVICA
(2021)
Article
Reproductive Biology
Razan Sakran, Svetlana Shechtman, Judy Arnon, Orna Diav-Citrin
Summary: This study found no increased risk of overall major anomalies or clinically important cardiac defects associated with ondansetron use during pregnancy. Both ondansetron and metoclopramide were associated with a lower rate of miscarriage compared to non-teratogenic exposure.
REPRODUCTIVE TOXICOLOGY
(2021)
Article
Pharmacology & Pharmacy
Peter Lipsky, Patrick T. Vallano, Jeffrey Smith, Walter Owens, Daniel Snider, Viswanath Bandaru, Yunfu Sun, Ross Wallingford, Joseph Duncan, Joshua Lewis, Jason Southall, Azeem Ansari, Hong Li
Summary: The study demonstrates the equivalence of Mylan's glatiramer acetate (MGA) to the reference product Copaxone(R) (COP) in terms of physicochemical properties, structural signatures, and biological activity. The findings provide compelling evidence that the FDA-approved generic MGA can be substituted for COP in the treatment of patients with relapsing-remitting multiple sclerosis.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Neurosciences
Amir Valizadeh, Mohammad Reza Fattahi, Maryam Sadeghi, Mehrnush Saghab Torbati, Mohammad Ali Sahraian, Amir Reza Azimi
Summary: The study found that DMTs can reduce the number and volume of T1 hypointense lesions in MS patients, but these findings need to be interpreted cautiously due to high heterogeneity values. The results suggest that DMTs have a certain impact on the progression of the disease in MS patients.
CNS NEUROSCIENCE & THERAPEUTICS
(2022)
Article
Ophthalmology
Laura De Giglio, Federico Sadun, Cinzia Roberti, Luigi Polidori, Marta Gilardi, Maria Concetta Altavista, Elena Maria Pennisi
Summary: A 74-year-old man experienced severe diplopia one month after recovering from a SARS-CoV-2 infection. Ophthalmological examination revealed bilateral exophthalmos and complex ocular motility disorder. Further tests confirmed the presence of concomitant Graves Disease and Myasthenia Gravis, which is rare following a viral infection. The recent SARS-CoV-2 infection may have triggered a complex autoimmune response.
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Ophthalmology
Valeria Albano, Rosanna Dammacco, Alessia Manni, Dario Sisto, Antonio Iaffaldano, Alberto Mavilio, Giovanni Alessio, Maria Trojano, Damiano Paolicelli
Summary: SD-OCT was used to evaluate the proportion of different macular ganglion cell-inner plexiform layer complex (mGCIP) defect patterns in multiple sclerosis patients without a history of optic neuritis (MSNON). The study found that a significant thinning of the mGCIP with inner defects was commonly observed in MSNON patients.
EUROPEAN JOURNAL OF OPHTHALMOLOGY
(2023)
Letter
Clinical Neurology
Emilio Portaccio, Maria Pia Amato
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Maria D'Apolito, Marianna G. G. Rispoli, Paola Ajdinaj, Anna Digiovanni, Valentina Tomassini, Luigia Gentile, Giovanna De Luca
NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Giacomo Boffa, Alessio Signori, Luca Massacesi, Alice Mariottini, Elvira Sbragia, Salvatore Cottone, Maria Pia Amato, Claudio Gasperini, Lucia Moiola, Stefano Meletti, Anna Maria Repice, Vincenzo Brescia Morra, Giuseppe Salemi, Francesco Patti, Massimo Filippi, Giovanna De Luca, Giacomo Lus, Mauro Zaffaroni, Patrizia Sola, Antonella Conte, Riccardo Nistri, Umberto Aguglia, Franco Granella, Simonetta Galgani, Luisa Maria Caniatti, Alessandra Lugaresi, Silvia Romano, Pietro Iaffaldano, Eleonora Cocco, Riccardo Saccardi, Emanuele Angelucci, Maria Trojano, Giovanni Luigi Mancardi, Maria Pia Sormani, Matilde Inglese
Summary: This study compared the effects of autologous hematopoietic stem cell transplantation (AHSCT) with other anti-inflammatory disease-modifying therapies (DMTs) on long-term disability worsening in active secondary progressive multiple sclerosis (SPMS). The results showed that AHSCT was associated with a slower disability progression and a higher likelihood of disability improvement compared to standard immunotherapy.
Correction
Clinical Neurology
Chiara Zanetta, Maria A. Rocca, Alessandro Meani, Vittorio Martinelli, Laura Ferre, Lucia Moiola, Massimo Filippi
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Sam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, Charles B. Malpas, Ibrahima Diouf, Nahid Moradi, Sifat Sharmin, Guillermo Izquierdo, Sara Eichau, Francesco Patti, Dana Horakova, Eva Kubala Havrdova, Alexandre Prat, Marc Girard, Pierre Duquette, Francois Grand Maison, Marco Onofrj, Alessandra Lugaresi, Pierre Grammond, Serkan Ozakbas, Maria Pia Amato, Oliver Gerlach, Patrizia Sola, Diana Ferraro, Katherine Buzzard, Olga Skibina, Jeannette Lechner-Scott, Raed Alroughani, Cavit Boz, Vincent Van Pesch, Elisabetta Cartechini, Murat Terzi, Davide Maimone, Cristina Ramo-Tello, Bassem Yamout, Samia Joseph Khoury, Daniele La Spitaleri, Maria Jose Sa, Yolanda Blanco, Franco Granella, Mark Slee, Ernest Butler, Youssef Sidhom, Riadh Gouider, Roberto Bergamaschi, Rana Karabudak, Radek Ampapa, Jose Luis Sanchez-Menoyo, Julie Prevost, Tamara Castillo-Trivino, Pamela A. McCombe, Richard Macdonell, Guy Laureys, Liesbeth Van Hijfte, Jiwon Oh, Ayse Altintas, Koen de Gans, Recai Turkoglu, Anneke van der Walt, Helmut Butzkueven, Steve Vucic, Michael Barnett, Edgardo Cristiano, Suzanne Hodgkinson, Gerardo Iuliano, Ludwig Kappos, Jens Kuhle, Vahid Shaygannejad, Aysun Soysal, Bianca Weinstock-Guttman, Bart Van Wijmeersch, Tomas Kalincik
Summary: This study compared primary and secondary progressive multiple sclerosis (PPMS, SPMS), and found that SPMS has later onset of the progressive phase and slower disability accrual, but higher baseline disability.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Raed Alroughani, Cavit Boz, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Sara Eichau, Marc Girard, Alexandre Prat, Pierre Duquette, Bassem Yamout, Samia J. Khoury, Seyed Aidin Sajedi, Recai Turkoglu, Ayse Altintas, Olga Skibina, Katherine Buzzard, Pierre Grammond, Rana Karabudak, Anneke van der Walt, Helmut Butzkueven, Davide Maimone, Jeannette Lechner-Scott, Aysun Soysal, Nevin John, Julie Prevost, Daniele Spitaleri, Cristina Ramo-Tello, Oliver Gerlach, Gerardo Iuliano, Matteo Foschi, Radek Ampapa, Vincent van Pesch, Michael Barnett, Nevin Shalaby, Marie D'hooghe, Jens Kuhle, Maria Jose Sa, Marzena Fabis-Pedrini, Allan Kermode, Saloua Mrabet, Riadh Gouider, Suzanne Hodgkinson, Guy Laureys, Liesbeth Van Hijfte, Richard Macdonell, Celia Oreja-Guevara, Edgardo Cristiano, Pamela McCombe, Jose Luis Sanchez-Menoyo, Bhim Singhal, Yolanda Blanco, Stella Hughes, Justin Garber, Claudio Solaro, Chris McGuigan, Bruce Taylor, Koen de Gans, Mario Habek, Abdullah Al-Asmi, Simu Mihaela, Tamara Castillo Trivino, Talal Al-Harbi, Juan Ignacio Rojas, Orla Gray, Dheeraj Khurana, Bart Van Wijmeersch, Nikolaos Grigoriadis, Jihad Inshasi, Jiwon Oh, Eduardo Aguera-Morales, Yara Fragoso, Fraser Moore, Cameron Shaw, Seyed Mohammad Baghbanian, Neil Shuey, Barbara Willekens, Todd A. Hardy, Danny Decoo, Angel Perez Sempere, Deborah Field, Ray Wynford-Thomas, Nick G. Cunniffe, Izanne Roos, Charles B. Malpas, Alasdair J. Coles, Tomas Kalincik, J. William L. Brown, MSBase Study Grp
Summary: This study found that early non-disabling relapses in people with RRMS are associated with a higher risk of disability accumulation, which may be mitigated by high-efficacy DMTs. Therefore, treatment decisions should take into account the impact of non-disabling relapses.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S. Freedman, Harold Atkins, Joachim Burman, Jennifer Massey, Ian Sutton, Barbara Withers, Richard Macdonell, Andrew Grigg, Oivind Torkildsen, Lars Bo, Anne Kristine Lehmann, Eva Kubala Havrdova, Eva Krasulova, Marek Trneny, Tomas Kozak, Anneke van der Walt, Helmut Butzkueven, Pamela McCombe, Olga Skibina, Jeannette Lechner-Scott, Barbara Willekens, Elisabetta Cartechini, Serkan Ozakbas, Raed Alroughani, Jens Kuhle, Francesco Patti, Pierre Duquette, Alessandra Lugaresi, Samia J. Khoury, Mark Slee, Recai Turkoglu, Suzanne Hodgkinson, Nevin John, Davide Maimone, Maria Jose Sa, Vincent van Pesch, Oliver Gerlach, Guy Laureys, Liesbeth Van Hijfte, Rana Karabudak, Daniele Spitaleri, Tunde Csepany, Riadh Gouider, Tamara Castillo-Trivino, Bruce Taylor, Basil Sharrack, John A. Snowden
Summary: This study compared the effectiveness of autologous hematopoietic stem cell transplant (AHSCT) with fingolimod, natalizumab, and ocrelizumab in treating relapsing-remitting multiple sclerosis (MS). The results showed that AHSCT was more effective than fingolimod and natalizumab in preventing relapses and facilitating recovery from disability. AHSCT had similar effectiveness to ocrelizumab.
Letter
Clinical Neurology
Viola Baione, Marco Canevelli, Daniele Belvisi, Maria Chiara Buscarinu, Gianmarco Bellucci, Roberta Fantozzi, Carolina Gabri Nicoletti, Giorgia Malatuni, Antonio Cortese, Laura De Giglio, Matteo Tartaglia, Gina Ferrazzano, Leonardo Malimpensa, Giorgio Leodori, Giuseppe Bruno, Elisabetta Ferraro, Girolama Alessandra Marfia, Diego Centonze, Marco Salvetti, Antonella Conte
Summary: Recent cross-sectional investigations have shown a relationship between Frailty Index (FI) and multiple sclerosis (MS). However, the association between frailty and relapse activity in MS is still unknown. A one-year follow-up study with 471 patients found that there was an inverse association between baseline FI score and the presence of relapse. These findings suggest that frailty may reflect the underlying mechanisms of MS disease activity and FI could be used as an enrichment criterion in clinical trials.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Psychology, Clinical
Marta Bassi, Luca Negri, Sabina Cilia, Monica Falautano, Monica Grobberio, Claudia Niccolai, Marianna Pattini, Erika Pietrolongo, Maria Esmeralda Quartuccio, Rosa Gemma Viterbo, Beatrice Allegri, Maria Pia Amato, Miriam Benin, Giovanna De Luca, Claudio Gasperini, Eleonora Minacapelli, Francesco Patti, Maria Trojano, Antonella Delle Fave
Summary: This study aimed to investigate the sense of coherence among caregiving partners of PwMS and its relationship with perceived social support and illness beliefs. The results showed that perceived support from family and beliefs concerning illness-related emotional representations, illness coherence, and treatment control significantly predicted participants' sense of coherence.
REHABILITATION PSYCHOLOGY
(2023)
Article
Clinical Neurology
Sifat Sharmin, Izanne Roos, Steve Simpson-Yap, Charles Malpes, Marina M. Sanchez, Serkan Ozakbas, Dana Horakova, Eva K. Havrdova, Francesco Patti, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Cavit Boz, Magd Zakaria, Marco Onofrj, Alessandra Lugaresi, Bianca Weinstock-Guttman, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Maria Pia Amato, Rana Karabudak, Francois Grand'Maison, Samia J. Khoury, Pierre Grammond, Jeannette Lechner-Scott, Katherine Buzzard, Olga Skibina, Anneke van der Walt, Helmut Butzkueven, Recai Turkoglu, Ayse Altintas, Davide Maimone, Allan Kermode, Nevin Shalaby, Vincent V. Pesch, Ernest Butler, Youssef Sidhom, Riadh Gouider, Saloua Mrabet, Oliver Gerlach, Aysun Soysal, Michael Barnett, Jens Kuhle, Stella Hughes, Maria J. Sa, Suzanne Hodgkinson, Celia Oreja-Guevara, Radek Ampapa, Thor Petersen, Cristina Ramo-Tello, Daniele Spitaleri, Pamela McCombe, Bruce Taylor, Julie Prevost, Matteo Foschi, Mark Slee, Chris McGuigan, Guy Laureys, Liesbeth V. Hijfte, Koen de Gans, Claudio Solaro, Jiwon Oh, Richard Macdonell, Eduardo Aguera-Morales, Bhim Singhal, Orla Gray, Justin Garber, Bart V. Wijmeersch, Mihaela Simu, Tamara Castillo-Trivino, Jose L. Sanchez-Menoyo, Dheeraj Khurana, Abdullah Al-Asmi, Talal Al-Harbi, Norma Deri, Yara Fragoso, Patrice H. Lalive, L. G. F. Sinnige, Cameron Shaw, Neil Shuey, Tunde Csepany, Angel P. Sempere, Fraser Moore, Danny Decoo, Barbara Willekens, Claudio Gobbi, Jennifer Massey, Todd Hardy, John Parratt, Tomas Kalincik
Summary: There are geographical variations in the incidence and prevalence of multiple sclerosis globally. Latitude, as well as other lifestyle and environmental factors, is considered to be a major driver of this variation. This study examined the risk of secondary progressive multiple sclerosis in relation to latitude and country of residence, with consideration of high-to-moderate efficacy immunotherapy, in a geographically diverse cohort. The findings suggest that higher latitude is associated with a higher probability of developing secondary progressive multiple sclerosis, but high-to-moderate efficacy immunotherapy can reduce this risk.
Article
Health Care Sciences & Services
Andrea Giordano, Silvia Testa, Marta Bassi, Sabina Cilia, Antonio Bertolotto, Maria Esmeralda Quartuccio, Erika Pietrolongo, Monica Falautano, Monica Grobberio, Claudia Niccolai, Beatrice Allegri, Rosa Gemma Viterbo, Paolo Confalonieri, Ambra Mara Giovannetti, Eleonora Cocco, Maria Grazia Grasso, Alessandra Lugaresi, Elisa Ferriani, Ugo Nocentini, Mauro Zaffaroni, Alysha De Livera, George Jelinek, Alessandra Solari, Rosalba Rosato
Summary: This study evaluated the performance of MCAT on the MSQOL-54 and found that it had satisfactory performance in assessing the quality of life of patients with multiple sclerosis. Compared to the full-length MSQOL-54, the simulated MCAT required fewer items without losing precision for the general HRQOL factor.
HEALTH AND QUALITY OF LIFE OUTCOMES
(2023)
Article
Clinical Neurology
Winston Dzau, Sifat Sharmin, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Alexandre Prat, Marc Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Serkan Ozakbas, Oliver Gerlach, Cavit Boz, Pierre Grammond, Murat Terzi, Maria Pia Amato, Daniele La Spitaleri, Cristina Ramo-Tello, Davide Maimone, Elisabetta Cartechini, Katherine Buzzard, Olga Skibina, Anneke van der Walt, Helmut Butzkueven, Gerardo Iuliano, Aysun Soysal, Tomas Kalincik
Summary: This study investigated the association between early progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) with the onset and disability accumulation of secondary progressive multiple sclerosis (SPMS). It found that early PIRA and RAW were associated with increased risk of SPMS, but not with the rate of disability progression during SPMS.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Manuela Altieri, Rocco Capuano, Alvino Bisecco, Alessandro d'Ambrosio, Mario Risi, Paola Cavalla, Marco Vercellino, Pietro Annovazzi, Mauro Zaffaroni, Nicola De Stefano, Maria Laura Stromillo, Emanuele 'Amico, Aurora Zanghi, Maria Chiara Buscarinu, Roberta Lanzillo, Giovanna De Luca, Massimiliano Calabrese, Lorena Lorefice, Massimiliano Di Filippo, Paola Valentino, Alberto Gajofatto, Girolama Alessandra Marfia, Aurora Fuiani, Viviana Nociti, Gioacchino Tedeschi, Antonio Gallo
Summary: The level of satisfaction of people with Multiple Sclerosis (pwMS) regarding the care received by the staff of Multiple Sclerosis Centers (MSCs) during the Covid-19 pandemic was assessed. The results showed that most pwMS did not change their therapy schedule and had little difficulty reaching their MSCs. Although only a small percentage had tele-health follow-up visits, the majority believed that telehealth services should be improved.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)